Guest guest Posted November 17, 2004 Report Share Posted November 17, 2004 Raven Biotechnologies Inc., of South San Francisco, submitted an investigational new drug application to begin a Phase I trial for RAV12, a therapeutic monoclonal antibody, in advanced-stage adenocarcinoma. The open-label, dose-escalation trial for RAV12 is planned to begin enrolling patients after clearance. The multicenter trial will include patients with colon, stomach or pancreatic cancer, or other target antigen-positive adenocarcinomas, including breast, lung and prostate. http://www.ravenbio.com/ __________________ Priscilla A. Savary Executive Director Colorectal Cancer Network PO Box 182, Kensington MD 20895 psavary@... www.colon-cancer.net _________ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.